NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating possible claims against the Credit Acceptance Corporation CACCand Phathom Pharmaceuticals, Inc. FAT. Our investigations address whether these companies have violated federal securities laws and/or engaged in other illegal business practices. For more information on each case, see the link provided.

credit acceptance company CACC

On January 4, 2023, information was released regarding the US Consumer Financial Protection Bureau and the New York State Office of the Attorney General filing a joint lawsuit against the company. The CFPB stated that the loan acceptance violated New York’s usury laws governing interest rates and other consumer and investor protection laws.

The Attorney General of New York seeks to stop Credit Acceptance’s abusive and deceptive practices, reform or void existing credit agreements, compensate affected New Yorkers, and seek penalties and damages for this unacceptable and illegal conduct.

Following this news, the company’s shares closed up 11.61% on January 4, 2023.

You can find more information about the credit acceptance check at: https://bespc.com/cases/CACC

Phathom Pharmaceuticals, Inc. FAT

On August 2, 2022, prior to the close of trading, Phathom issued a press release titled, “Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates,” announcing that “in our post-market approval, we have detected trace amounts of nitrosamines in vonoprazan drugs as we prepared for commercial launch.” The press release also announced that “[t]The Company is working with the FDA and plans to approve and implement an additional test method, specification, including a proposed acceptable intake limit, and additional controls to address this contamination prior to commercializing our first Vonoprazan-based products.” Finally ,…